Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases.

Blackman MA, Marchionni MA, Gilly J, Hepburn M, Innis BL, Barrett ADT, Kester KE, Mascola JR, Cummings JF, Monath TP, Cassetti MC, Kim JH, Saville M, Thomas SJ.

Vaccine. 2019 Sep 6. pii: S0264-410X(19)31137-5. doi: 10.1016/j.vaccine.2019.08.061. [Epub ahead of print]

PMID:
31500964
2.

Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations.

Innis BL, Scorza FB, Blum JS, Jain VK, Aguilar AO, Post DJ, Roberts PC, Wairagkar N, White J, Bresee J.

Vaccine. 2019 Aug 14;37(35):4830-4834. doi: 10.1016/j.vaccine.2019.06.053.

3.

Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity.

Innis BL, Berlanda Scorza F, Blum JS, Jain VK, Older Aguilar A, Post DJ, Roberts PC, Wairagkar N, White J, Bresee J.

Vaccine. 2019 Aug 14;37(35):4823-4829. doi: 10.1016/j.vaccine.2019.06.080.

4.

Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine.

Danier J, Rivera L, Claeys C, Dbaibo G, Jain VK, Kosalaraksa P, Woo W, Yanni E, Zaman K, Acosta B, Amanullah A, Ariza M, Luisa Arroba Basanta M, Bavdekar A, Carmona A, Cousin L, Diaz A, Diez-Domingo J, Cagri Dinleyici E, Faust SN, Garcia-Sicilia J, Gomez-Go GD, Antionette Gonzales L, Hacimustafaoglu M, Hughes SM, Izu A, Jackowska T, Kant S, Lucero M, Mares Bermudez J, Martinón-Torres F, Montellano M, Prymula R, Puthanakit T, Ruzkova R, Sadowska-Krawczenko I, Soni J, Szymanski H, Ulied A, Schuind A, Innis BL; Flu4VEC Study Group.

Pediatr Infect Dis J. 2019 Aug;38(8):866-872. doi: 10.1097/INF.0000000000002387.

PMID:
31306399
5.

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost.

Levine MZ, Holiday C, Jefferson S, Gross FL, Liu F, Li S, Friel D, Boutet P, Innis BL, Mallett CP, Tumpey TM, Stevens J, Katz JM.

NPJ Vaccines. 2019 May 29;4:22. doi: 10.1038/s41541-019-0114-8. eCollection 2019.

6.

Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.

Choi A, Bouzya B, Cortés Franco KD, Stadlbauer D, Rajabhathor A, Rouxel RN, Mainil R, Van der Wielen M, Palese P, García-Sastre A, Innis BL, Krammer F, Schotsaert M, Mallett CP, Nachbagauer R.

Immunohorizons. 2019 Apr 1;3(4):133-148. doi: 10.4049/immunohorizons.1900022.

7.

Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.

Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A, Tavares Da Silva F, Rappuoli R, Garçon N, Innis BL.

Vaccine. 2019 May 21;37(23):3006-3021. doi: 10.1016/j.vaccine.2019.04.048. Epub 2019 Apr 25. Review.

8.

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.

Moris P, Bauer KM, Currier JR, Friberg H, Eckels KH, Esquilin IO, Gibbons RV, Innis BL, Jarman RG, Simasathien S, Sun P, Thomas SJ, Watanaveeradej V.

Hum Vaccin Immunother. 2019 Mar 4:1-16. doi: 10.1080/21645515.2019.1581536. [Epub ahead of print]

PMID:
30829100
9.

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.

Claeys C, Chandrasekaran V, García-Sicilia J, Prymula R, Díez-Domingo J, Brzostek J, Marès-Bermúdez J, Martinón-Torres F, Pollard AJ, Růžková R, Carmona Martinez A, Ulied A, Miranda Valdivieso M, Faust SN, Snape MD, Friel D, Ollinger T, Soni J, Schuind A, Li P, Innis BL, Jain VK.

Pediatr Infect Dis J. 2019 Feb;38(2):203-210. doi: 10.1097/INF.0000000000002217.

10.

Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons.

Claeys C, Zaman K, Dbaibo G, Li P, Izu A, Kosalaraksa P, Rivera L, Acosta B, Arroba Basanta ML, Aziz A, Cabanero MA, Chandrashekaran V, Corsaro B, Cousin L, Diaz A, Diez-Domingo J, Dinleyici EC, Faust SN, Friel D, Garcia-Sicilia J, Gomez-Go GD, Antoinette Gonzales ML, Hughes SM, Jackowska T, Kant S, Lucero M, Malvaux L, Mares Bermudez J, Martinon-Torres F, Miranda M, Montellano M, Peix Sambola MA, Prymula R, Puthanakit T, Ruzkova R, Sadowska-Krawczenko I, Salamanca de la Cueva I, Sokal E, Soni J, Szymanski H, Ulied A, Schuind A, Jain VK, Innis BL; Flu4VEC Study Group.

Lancet Child Adolesc Health. 2018 May;2(5):338-349. doi: 10.1016/S2352-4642(18)30062-2. Epub 2018 Mar 5.

PMID:
30169267
11.

Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.

Claeys C, Drame M, García-Sicilia J, Zaman K, Carmona A, Tran PM, Miranda M, Martinón-Torres F, Thollot F, Horn M, Schwarz TF, Behre U, Merino JM, Sadowska-Krawczenko I, Szymański H, Schu P, Neumeier E, Li P, Jain VK, Innis BL.

BMC Infect Dis. 2018 Apr 18;18(1):186. doi: 10.1186/s12879-018-3079-8.

12.

Immunization against Hepatitis E.

Innis BL, Lynch JA.

Cold Spring Harb Perspect Med. 2018 Nov 1;8(11). pii: a032573. doi: 10.1101/cshperspect.a032573. Review.

PMID:
29530951
13.

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J.

Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7.

14.

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.

Diaz C, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, De La Barrera R, Lepine E, Toussaint JF, Febo I, Innis BL, Thomas SJ, Schmidt AC.

Am J Trop Med Hyg. 2018 May;98(5):1435-1443. doi: 10.4269/ajtmh.17-0627. Epub 2018 Mar 1.

15.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.

Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL.

Vaccine. 2017 Nov 1;35(46):6321-6328. doi: 10.1016/j.vaccine.2017.09.012. Epub 2017 Oct 5.

16.

Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.

Madan A, Collins H, Sheldon E, Frenette L, Chu L, Friel D, Drame M, Vaughn DW, Innis BL, Schuind A.

Vaccine. 2017 Aug 16;35(35 Pt B):4621-4628. doi: 10.1016/j.vaccine.2017.07.013. Epub 2017 Jul 15.

17.

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States.

Schmidt AC, Lin L, Martinez LJ, Ruck RC, Eckels KH, Collard A, De La Barrera R, Paolino KM, Toussaint JF, Lepine E, Innis BL, Jarman RG, Thomas SJ.

Am J Trop Med Hyg. 2017 Jun;96(6):1325-1337. doi: 10.4269/ajtmh.16-0634.

18.

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.

Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, Bekkat-Berkani R.

Hum Vaccin Immunother. 2017 Jul 3;13(7):1640-1652. doi: 10.1080/21645515.2017.1313375. Epub 2017 May 22. Review.

19.

Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.

Berry AA, Abu-Elyazeed R, Diaz-Perez C, Mufson MA, Harrison CJ, Leonardi M, Twiggs JD, Peltier C, Grogg S, Carbayo A, Shapiro S, Povey M, Baccarini C, Innis BL, Henry O.

Hum Vaccin Immunother. 2017 Jul 3;13(7):1516-1522. doi: 10.1080/21645515.2017.1309486. Epub 2017 May 8.

20.

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.

Madan A, Ferguson M, Rheault P, Seiden D, Toma A, Friel D, Soni J, Li P, Innis BL, Schuind A.

Vaccine. 2017 Apr 4;35(15):1865-1872. doi: 10.1016/j.vaccine.2017.02.057. Epub 2017 Mar 13.

21.

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.

Madan A, Ferguson M, Sheldon E, Segall N, Chu L, Toma A, Rheault P, Friel D, Soni J, Li P, Innis BL, Schuind A.

Vaccine. 2017 Mar 7;35(10):1431-1439. doi: 10.1016/j.vaccine.2017.01.054. Epub 2017 Feb 7.

22.

Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.

Jain VK, Domachowske JB, Wang L, Ofori-Anyinam O, Rodríguez-Weber MA, Leonardi ML, Klein NP, Schlichter G, Jeanfreau R, Haney BL, Chu L, Harris JS, Sarpong KO, Micucio AC, Soni J, Chandrasekaran V, Li P, Innis BL.

J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):9-19. doi: 10.1093/jpids/piw068.

23.

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.

Madan A, Segall N, Ferguson M, Frenette L, Kroll R, Friel D, Soni J, Li P, Innis BL, Schuind A.

J Infect Dis. 2016 Dec 1;214(11):1717-1727. Epub 2016 Sep 7.

24.

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

Canelle Q, Dewé W, Innis BL, van der Most R.

Hum Vaccin Immunother. 2016 Sep;12(9):2289-98. doi: 10.1080/21645515.2016.1168954. Epub 2016 Apr 22.

25.

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children.

Watanaveeradej V, Simasathien S, Mammen MP, Nisalak A, Tournay E, Kerdpanich P, Samakoses R, Putnak RJ, Gibbons RV, Yoon IK, Jarman RG, De La Barrera R, Moris P, Eckels KH, Thomas SJ, Innis BL.

Am J Trop Med Hyg. 2016 Jun 1;94(6):1348-1358. doi: 10.4269/ajtmh.15-0659. Epub 2016 Mar 28.

26.

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.

Nachbagauer R, Kinzler D, Choi A, Hirsh A, Beaulieu E, Lecrenier N, Innis BL, Palese P, Mallett CP, Krammer F.

NPJ Vaccines. 2016;1. pii: 16015. doi: 10.1038/npjvaccines.2016.15. Epub 2016 Sep 22.

27.

Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.

Bekkat-Berkani R, Ray R, Jain VK, Chandrasekaran V, Innis BL.

Expert Rev Vaccines. 2016;15(2):201-14. doi: 10.1586/14760584.2016.1113878. Epub 2015 Dec 5. Review.

PMID:
26641539
28.

Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.

Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, Povey M, Da Costa C, Nicholson O, Innis BL.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):339-48. doi: 10.1093/jpids/piu081. Epub 2014 Aug 7.

29.

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.

Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):170-9. doi: 10.1093/jpids/piv041. Epub 2015 Jul 16.

30.

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.

Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, Halperin SA, Li P, Liu A, McNeil S, Mendez LP, Rivera L, Innis BL, Jain VK.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):242-51. doi: 10.1093/jpids/piu098. Epub 2014 Oct 20.

31.

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease.

Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, McElhaney JE, Oostvogels L, van Essen GA, Gaglani M, Jackson LA, Vesikari T, Legrand C, Tibaldi F, Innis BL, Dewé W.

Open Forum Infect Dis. 2015 May 14;2(2):ofv067. doi: 10.1093/ofid/ofv067. eCollection 2015 Apr.

32.

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.

Bauer K, Esquilin IO, Cornier AS, Thomas SJ, Quintero Del Rio AI, Bertran-Pasarell J, Morales Ramirez JO, Diaz C, Carlo S, Eckels KH, Tournay E, Toussaint JF, De La Barrera R, Fernandez S, Lyons A, Sun W, Innis BL.

Am J Trop Med Hyg. 2015 Sep;93(3):441-453. doi: 10.4269/ajtmh.14-0625. Epub 2015 Jul 14.

33.

AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.

Mallett CP, Beaulieu E, Joly MH, Baras B, Lu X, Liu F, Levine MZ, Katz JM, Innis BL, Giannini SL.

Vaccine. 2015 Jul 31;33(32):3784-7. doi: 10.1016/j.vaccine.2015.06.053. Epub 2015 Jun 19.

34.

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.

Schuind A, Segall N, Drame M, Innis BL.

J Infect Dis. 2015 Aug 15;212(4):531-41. doi: 10.1093/infdis/jiv091. Epub 2015 Feb 25.

35.

An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.

Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, Malice MP, Festraets P, Warter L, Putnak JR, Eckels KH.

Am J Trop Med Hyg. 2015 Apr;92(4):698-708. doi: 10.4269/ajtmh.14-0268. Epub 2015 Feb 2.

36.

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.

Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF.

Hum Vaccin Immunother. 2014;10(10):2942-57. doi: 10.4161/21645515.2014.972149. Epub 2014 Nov 21.

37.

Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.

Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.

Pediatr Infect Dis J. 2014 Dec;33(12):1262-9. doi: 10.1097/INF.0000000000000463.

PMID:
25386965
38.

AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.

Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, Godeaux O, Izurieta P, Vaughn DW.

J Infect Dis. 2015 Mar 1;211(5):801-10. doi: 10.1093/infdis/jiu548. Epub 2014 Oct 6.

39.

Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.

Sasadeusz J, Prince HM, Schwarer A, Szer J, Stork A, Bock HL, Povey M, Nicholson O, Innis BL.

Transpl Infect Dis. 2014 Dec;16(6):1024-31. doi: 10.1111/tid.12295. Epub 2014 Oct 1.

PMID:
25272081
40.

Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.

Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A, Tournay E, De La Barrerra R, Dessy F, Toussaint JF, Eckels KH, Thomas SJ, Innis BL.

Am J Trop Med Hyg. 2014 Jul;91(1):119-28. doi: 10.4269/ajtmh.13-0452. Epub 2014 May 27.

41.

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines.

van Essen GA, Beran J, Devaster JM, Durand C, Duval X, Esen M, Falsey AR, Feldman G, Gervais P, Innis BL, Kovac M, Launay O, Leroux-Roels G, McElhaney JE, McNeil S, Oujaa M, Richardus JH, Ruiz-Palacios G, Osborne RH, Oostvogels L.

Influenza Other Respir Viruses. 2014 Jul;8(4):452-62. doi: 10.1111/irv.12245. Epub 2014 Apr 4.

42.

Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.

Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW.

J Infect Dis. 2014 Aug 15;210(4):545-57. doi: 10.1093/infdis/jiu173. Epub 2014 Mar 20.

43.

Vaccine for prevention of influenza in children.

Jain VK, Dbaibo G, Innis BL.

N Engl J Med. 2014 Mar 20;370(12):1167-8. doi: 10.1056/NEJMc1400874. No abstract available.

PMID:
24645953
44.

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.

Jain VK, Chandrasekaran V, Wang L, Li P, Liu A, Innis BL.

BMC Infect Dis. 2014 Mar 10;14:133. doi: 10.1186/1471-2334-14-133.

45.

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.

Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.

Vaccine. 2014 Mar 14;32(13):1480-7. doi: 10.1016/j.vaccine.2014.01.022. Epub 2014 Jan 28.

46.

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.

Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, Stefkovičova M, Usonis V, Wysocki J, Douha M, Vassilev V, Nicholson O, Innis BL, Willems P.

Lancet. 2014 Apr 12;383(9925):1313-24. doi: 10.1016/S0140-6736(12)61461-5. Epub 2014 Jan 29.

PMID:
24485548
47.

Evaluation of dengue virus strains for human challenge studies.

Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RC, Eckels KH, Putnak R, Kanesa-thasan N, Scherer JM, Statler J, Asher LV, Thomas SJ, Vaughn DW.

Vaccine. 2014 Mar 14;32(13):1488-94. doi: 10.1016/j.vaccine.2013.12.040. Epub 2014 Jan 24.

PMID:
24468542
48.

Vaccine for prevention of mild and moderate-to-severe influenza in children.

Jain VK, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, Quiambao BP, Rivera-Medina DM, Kerdpanich P, Ceyhan M, Dinleyici EC, Cravioto A, Yunus M, Chanthavanich P, Limkittikul K, Kurugol Z, Alhan E, Caplanusi A, Durviaux S, Boutet P, Ofori-Anyinam O, Chandrasekaran V, Dbaibo G, Innis BL.

N Engl J Med. 2013 Dec 26;369(26):2481-91. doi: 10.1056/NEJMoa1215817. Epub 2013 Dec 11.

49.

A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU).

Gibbons RV, Nisalak A, Yoon IK, Tannitisupawong D, Rungsimunpaiboon K, Vaughn DW, Endy TP, Innis BL, Burke DS, Mammen MP Jr, Scott RM, Thomas SJ, Hoke CH Jr.

Vaccine. 2013 Sep 23;31(41):4487-500. doi: 10.1016/j.vaccine.2013.07.082. Epub 2013 Aug 8. Review.

PMID:
23933334
50.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343.

Supplemental Content

Loading ...
Support Center